drugset / Trial / NCT01084876

Demonstrate Efficacy and Safety of Metastatic Breast Cancer

NCT01084876

Phase 3 Completed 475 enrolled Celltrion
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the study is to demonstrate equivalence

Timeline

Start
2010-06
Primary completion
2012-07
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Trastuzumab Monoclonal antibody 6 mg/kg Intravenous
Background Paclitaxel Small molecule 175 mg/m2 Intravenous

Indications